A clustered family history of breast, ovarian, and colon cancers appropriately triggered germline testing, with BRCA1 mutation status informing individualized risk stratification and counseling.

Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among ...

Women who knew their BRCA+ status were diagnosed with earlier stage breast cancer, needed less chemotherapy, less extensive surgery, and had greater overall 5-year survival (98 percent vs. 74 percent) ...

More women may benefit from gene testing for hereditary breast or ovarian cancer, especially if they’ve already survived cancer once, according to new recommendations from experts in preventive ...

BRCA1 and BRCA2 gene mutations increase the risk of hereditary breast cancer. Here's what you should know about the causes, genetic testing options, and prevention strategies to manage your cancer ...

Seven women in one family had major surgery after a widely used genetic test, taken by hundreds of thousands of people, showed a high cancer risk. But years later, the family has learned the results ...

ROANOKE, Va. – It’s estimated that more than 42,000 people will die from breast cancer this year, according to the American Cancer Society. To help you understand if you’re at a greater risk of ...

Women with breast cancer who were also carriers of the BRCA1 or BRCA2 mutation and received textured breast implants as part of their reconstructive surgery after mastectomy were 16 times more likely ...

Olaparib plus abiraterone and prednisone or prednisolone already is approved in the European Union and several other countries. The FDA today approved olaparib (Lynparza) when used in combination with ...